Trending Healthcare Stocks on the Run – Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Medtronic plc. Ordinary Shares (NYSE:MDT)
On Tuesday, Valeant Pharmaceuticals Intl Inc (NYSE:VRX), surge 6.73% to $10.31 & Medtronic plc. Ordinary Shares (NYSE:MDT), gained 1.21% to $84.75.
During the last trading session Valeant Pharmaceuticals Intl Inc the minimum price at which share is traded was $9.92 and peak price of the day was $10.49. On May 1, 2017, Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) declared that, following the earlier-than-predictable closing of the sale of three skincare brands to L’Oréal and the closing of the divestiture of a manufacturing facility in Brazil, it has reduced its senior secured terms loans by about an additional $220 million as of Monday May 1, 2017. In aggregate, the company has now reduced about $3.6 billion of debt from the end of first quarter 2016.
The company continues to advance toward its expectation of paying down $5 billion in debt from divestiture proceeds and free cash flow within 18 months of August 2016.
On the other hand, Medtronic plc. Ordinary Shares (NYSE:MDT), manufactures and sells device-based medical therapies worldwide. The company’s Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators and cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular intervention products, and products to treat superficial and deep venous diseases. The Company has 1.37B shares outstanding while EPS in next five years is expected to reach 7.37 % while EPS growth in past 5 year was -2.60 %. On May 1, 2017, Medtronic plc (MDT) declared the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute Onyx(TM) Drug-Eluting Stent (DES). The Resolute Onyx DES builds on the proven clinical performance and superior deliverability of the Resolute Integrity(TM) DES to further strengthen the gold standard safety and efficacy of DES technology.
“As stent technologies continue to evolve, recent clinical studies have shown that newer technologies have not established a clinical advantage over durable polymer DES,” said Roxana Mehran, M.D., cardiologist and professor of medicine at Mount Sinai School of Medicine in New York City. “The Resolute Onyx DES provides physicians with additional 4.5 mm and 5.0 mm sizes to treat patients with large coronary anatomies, while the stent`s improved visibility and excellent deliverability further differentiates it from other drug-eluting stents on the market.”
“We set out to expand upon a proven DES technology to enhance clinical performance and deliver further meaningful innovations that address the needs of interventional cardiologists around the globe,” said Jason Weidman, vice president and general manager of the Coronary and Renal Denervation business, which is part of the Cardiac and Vascular Group at Medtronic. “Already making a noteworthy impact outside of the U.S., the Resolute Onyx DES with Core Wire Technology exemplifies our commitment to advancing our DES portfolio by combining cutting-edge engineering with proven components for a wide range of patients.”